Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001371 · ClinicalTrials.gov registry record
A Pilot Study of Topical Antiflammin-2 for Psoriasis
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 24
- Enrollment target
NCT00001371: Completed study, sponsored by National Cancer Institute (NCI).
NCT00001371 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001371 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This study is a pilot trial designed to evaluate topical antiflammin-2, a phospholipase A2 (PLA2) inhibitor, in the treatment of chronic plaque psoriasis. Antiflammin-2 in an ointment base, or the vehicle alone will each be applied four times per day to a single plaque in a randomized, double-blinded fashion.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1993-12 |
| Est. Completion | 2000-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001371
The ClinicalTrials.gov registry entry for NCT00001371 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00001371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001371 about?
NCT00001371 is a clinical study titled "A Pilot Study of Topical Antiflammin-2 for Psoriasis". This study is a pilot trial designed to evaluate topical antiflammin-2, a phospholipase A2 (PLA2) inhibitor, in the treatment of chronic plaque psoriasis. Antiflammin-2 in an ointment base, or the vehicle alone will each be applied four times per day to a single plaque in a randomized, double-blinde...
What is the current status of trial NCT00001371?
This trial is currently completed. The enrollment target is 24 participants. The study started on 1993-12. Estimated completion is 2000-12.
Who is sponsoring clinical trial NCT00001371?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.